Katherine Carias, MD
Allergy/ Immunology · Ashland, KYNPI 1205828282
Payments from drug & device makers
Across 131 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$914
- GSK$338
- Pharming Healthcare, Inc.$318
- Genentech USA, Inc.$303
- AstraZeneca$198
- Grifols USA, LLC$178
- plus $879 from 18 others
What the payments were for
- Consulting fees$110%
- Food & beverage$3,02597%
- Education$933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 47 | $914 |
| GSK | 13 | $338 |
| Pharming Healthcare, Inc. | 3 | $318 |
| Genentech USA, Inc. | 9 | $303 |
| AstraZeneca | 11 | $198 |
| Grifols USA, LLC | 9 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Alk-abello, Inc | 1 | $128 |
| Regeneron Healthcare Solutions, Inc. | 4 | $117 |
| Mylan Specialty L.p. | 3 | $62 |
| ADMA Biomanufacturing LLC | 3 | $45 |
| Pfizer | 2 | $43 |
| Optinose US, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Blueprint Medicines Corporation | 2 | $35 |
| Lundbeck LLC | 2 | $35 |
| Kaleo, Inc. | 2 | $34 |
| Merck | 2 | $31 |
| Amgen | 2 | $29 |
| Lilly USA, LLC | 1 | $23 |
| Novartis | 1 | $19 |
| Biocryst US Sales Co., LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy/ immunology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AscenivImmune Globulin,gamma(Igg)slra | 11 | $409,681 |
| EliquisApixaban | 754 | $225,807 |
| Dupixent PenDupilumab | 27 | $100,694 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $87,786 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $75,061 |
| XareltoRivaroxaban | 173 | $51,063 |
| OzempicSemaglutide | 48 | $49,464 |
| UzedyRisperidone | 11 | $37,033 |
| XifaxanRifaximin | 19 | $36,766 |
| LinzessLinaclotide | 60 | $34,546 |
| JardianceEmpagliflozin | 111 | $34,356 |
| NuedextaDextromethorphan Hbr/Quinidine | 39 | $29,100 |
| Potassium Chloride | 672 | $23,126 |
| Spiriva RespimatTiotropium Bromide | 36 | $19,773 |
| MyrbetriqMirabegron | 75 | $17,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $225,807754 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $338 | $114,355185 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $147 | $75,06115 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $17 | $54,129147 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $35 | $37,03311 claims |
| AstraZenecaFarxiga, Symbicort | $198 | $24,52676 claims |
| MerckJanuvia, Dulera | $31 | $22,21870 claims |
| Lilly USA, LLCMounjaro, Trulicity | $23 | $18,17242 claims |
| NovartisEntresto | $19 | $13,85339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Ashland
- Charles SmithLouisville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.